



Cyramza® (ramucirumab)

Last Review Date: May 1st, 2018

Number: MG.MM.PH.48

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Cyramza (ramucirumab) is a vascular endothelial growth factor (VEGF) receptor 2 antagonist that inhibits ligand-stimulated activation of the VEGF receptor 2, ligand-induced proliferation, and migration of human endothelial cells. Unlike all clinically approved angiogenesis inhibitors, the fully human monoclonal antibody ramucirumab, specifically inhibits VEGFR-2.

Dosing

Max Units (per dose and over time):

- Gastric, Esophageal and Gastro-esophageal Junction, and Colorectal cancer: 180 billable units every 14 days
- NSCLC: 240 billable units every 21 days

Guideline

Cyramza (ramucirumab) may be considered medically necessary for the following diagnosis when all of the following criteria are met:

Gastric, Esophageal and Gastro-esophageal Junction Cancers, initiation:

- Patient is 18 years of age or older; **AND**
- Patient has advanced or metastatic disease; **AND**
- Used as a single agent OR in combination with paclitaxel; **AND**
- Must be used as subsequent therapy, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy

Non-small cell lung cancer, initiation:

- Patient is 18 years of age or older; **AND**
- Patient's disease is metastatic; **AND**
- Used as subsequent therapy following progression on or after platinum-based chemotherapy; **AND**
- Cyramza must be used in combination with docetaxel; **AND**
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Cyramza

Colorectal cancer, initiation

- Patient is 18 years of age or older; **AND**
- Patient's disease is metastatic; **AND**
- Cyramza is being used in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for metastatic disease that progressed on or after therapy with bevacizumab, oxaliplatin and a fluoropyrimidine

Coverage for Cyramza (ramucirumab) may be renewed when the following criteria are met:

- Disease response; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: hemorrhage, arterial thrombotic events, uncontrollable hypertension, infusion-related reactions, severe proteinuria (> 3g/24h), gastrointestinal perforation, wound healing complications, etc.

Limitations/Exclusions

- Approval will be granted for 6 months, and may be renewed
- Ramucirumab is considered investigational, and may not be considered medically necessary for the following conditions: bladder cancer, breast cancer, chondrosarcoma, genitourinary tumor, fallopian tube cancer, head and neck cancer, hepatocellular cancer, malignant pleural diseases, melanoma, ovarian cancer, peritoneal carcinoma, prostate cancer, renal cell carcinoma, soft tissue sarcoma

Applicable Procedure Codes

J9308	Injection, ramucirumab, 5 mg
-------	------------------------------

Applicable Diagnosis Codes

C 15.3	Malignant neoplasm of upper third of esophagus
C 15.4	Malignant neoplasm of middle third of esophagus
C 15.5	Malignant neoplasm of lower third of esophagus
C 15.8	Malignant neoplasm of overlapping sites of esophagus
C 15.9	Malignant neoplasm of esophagus, unspecified
C 16.0	Malignant neoplasm of cardia
C 16.1	Malignant neoplasm of fundus of stomach

C 16.2	Malignant neoplasm of body of stomach
C 16.3	Malignant neoplasm of pyloric antrum
C 16.4	Malignant neoplasm of pylorus
C 16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C 16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C 16.8	Malignant neoplasm of overlapping sites of stomach
C 16.9	Malignant neoplasm of stomach, unspecified
C 17.0	Malignant neoplasm duodenum
C 17.1	Malignant neoplasm jejunum
C 17.2	Malignant neoplasm ileum
C 17.8	Malignant neoplasm of overlapping sites of small intestines
C 17.9	Malignant neoplasm of small intestine, unspecified
C 18.0	Malignant neoplasm of cecum
C 18.1	Malignant neoplasm of appendix
C 18.2	Malignant neoplasm of ascending colon
C 18.3	Malignant neoplasm of hepatic flexure
C 18.4	Malignant neoplasm of transverse colon
C 18.5	Malignant neoplasm of splenic flexure
C 18.6	Malignant neoplasm of descending colon
C 18.7	Malignant neoplasm of sigmoid colon
C 18.8	Malignant neoplasm of overlapping sites of large intestines
C 18.9	Malignant neoplasm of colon, unspecified
C 19	Malignant neoplasm of rectosigmoid junction
C 20	Malignant neoplasm of rectum
C 21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C 33	Malignant neoplasm of trachea
C 34.00	Malignant neoplasm of main bronchus
C 34.01	Malignant neoplasm of right main bronchus
C 34.02	Malignant neoplasm of left main bronchus
C 34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C 34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C 34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C 34.2	Malignant neoplasm of middle lobe, bronchus or lung
C 34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C 34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C 34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C 34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C 34.81	Malignant neoplasm of overlapping sites of right bronchus and lung

C 34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C 34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C 34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C 34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C 78.00	Secondary malignant neoplasm of lung
C 78.01	Secondary malignant neoplasm of lung
C 78.02	Secondary malignant neoplasm of lung
C 78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C 78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
D 37.1	Neoplasm of uncertain behavior of stomach
D 37.8	Neoplasm of uncertain behavior of other specified digestive organs
D 37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
Z 85.00	Personal history of malignant neoplasm of unspecified digestive organ
Z 85.01	Personal history of malignant neoplasm of esophagus
Z 85.028	Personal history of other malignant neoplasm of stomach
Z 85.038	Personal history of malignant neoplasm of large intestine
Z 85.118	Personal history of other malignant neoplasm of bronchus and lung

References

1. Cyramza [package insert]. Indianapolis, IN; Eli Lilly and Company; March 2017. Accessed January 2018.
2. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): A novel attack on angiogenesis. *Future Oncol.* 2010;6(7):1085-1094.
3. U.S. Food and Drug Administration (FDA). FDA approves Cyramza for stomach cancer. Press Announcement. Silver Spring, MD: FDA; April 21, 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed April 23, 2014.
4. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2014 Jan 4; 383(9911):31-9. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.
5. Referenced with permission from the NCCN Drugs and Biologics Compendium (NCCN Compendium) for ramucirumab. National Comprehensive Cancer Network, 2018. The NCCN Compendium is a derivative work of the NCCN Guidelines. NATIONAL COMPREHENSIVE CANCER NETWORK, NCCN, and NCCN GUIDELINES are trademarks owned by the National Comprehensive Cancer Network, Inc." To view the most recent and complete version of the Compendium, go online to NCCN.org.